Alivus Life Sciences Ltd

- Some backlog orders from the previous quarter due to shipping and supply chain issues (notably Red Sea disruptions) were cleared and reflected in the current quarter's revenue. - However, some backlog still remains and has been incorporated into ongoing planning. - The current quarter itself has created new backlog, which will carry over into the next quarter. - Improved planning has helped address shipment delays to a large extent, stabilizing order fulfillment. - Overall, the backlog situation is being actively managed but is not completely resolved yet, awaiting improvement in global shipping conditions.

- Glenmark Life Sciences does not plan to raise debt for expansion; all expansion will be funded through internal accruals. - The company aims to remain debt-free, with no requirement for leveraging the balance sheet at this stage. - There was no mention of any immediate or future equity fundraising in the transcript. - Current capex plans for FY '25 are between INR 300-350 crores, funded internally. - The company may retain some cash on the balance sheet due to high capex commitment, leading to moderate dividend payout, but not specifying any fundraising through equity.

- Current year (FY'25) capex planned between INR 300 crores to INR 340 crores. - Major investment toward building greenfield site at Solapur, expected completion in about 18-20 months; total Solapur capex around INR 350-400 crores. - Addition of new pharma capacity at Ankleshwar and Dahej plants (e.g., pharma modules in Q2 and Q4 FY'25). - Investing in new R&D center to support expansion into new technology platforms and portfolio avenues with backing from Nirma. - Capex to meet environmental regulations continues, including commissioning of third Effluent Treatment Plant (ETP) next month; any additional environmental capex expected to be marginal. - Capex investment will be calibrated to align with demand, product mix, and regulatory approvals without overinvestment. - Expansion funded through internal accruals; no new debt planned. - Strategic focus on building specialty and CDMO business segments.

- FY '25 started positively with close to 10% sequential revenue growth, indicating a strong and resilient business. - Broad-based growth witnessed across geographies including India, Japan, and Rest of the World. - Medium-term growth outlook remains unchanged with expectations of mid- to high-teens growth for the external business. - Brownfield expansions have provided a runway of about 1.5 years to cater to additional demand. - New greenfield Solapur facility under construction, expected to be completed in 18 to 20 months, will further boost capacity. - CDMO segment expected to pick up from Q3 FY '25, with additional projects in the pipeline and steady momentum. - Pipeline continuously being filled, with 5 new products added recently; 20 high-potency APIs targeting a $4 billion market. - Demand outlook is improving with increasing momentum in specialty and innovator segments.

- Glenmark Life Sciences started FY '25 on a positive note with close to 10% sequential growth, indicating a strong and resilient business. - The demand outlook is good, with growth expected to continue across regions over the next couple of quarters. - The medium-term growth outlook remains unchanged with additional capacity coming online (e.g., Solapur Phase I to complete in 18-20 months). - EBITDA margins are stable at around 28%, with expectations to maintain or improve margins from current levels. - Gross margins have faced pressure due to product mix and the discontinuation of PLI benefits but are not expected to decline further. - Free cash flow generation is strong, supporting capex and potentially steady dividend payout, although dividend growth payout may moderate. - Continued investment in capacity expansion (INR300-350 crores capex in FY '25) supports future revenue growth. - Overall, stable margins with mid-to-high teens growth in external business revenues are anticipated.